Patents
Literature
8 results about "Amniotic epithelial cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An amniotic epithelial cell is a form of stem cell extracted from the lining of the inner membrane of the placenta. Amniotic epithelial cells start to develop around 8 days post fertilization. These cells are known to have some of the same markers as embryonic stem cells, more specifically, Oct-4 and nanog. These transcription factors are the basis of the pluripotency of stem cells. Amniotic epithelial cells have the ability to develop into any of the three germ layers: endoderm, mesoderm, and ectoderm. They can develop into several organ tissues specific to these germ layers including heart, brain, and liver. The pluripotency of the human amniotic epithelial cells makes them useful in treating and fighting diseases and disorders of the nervous system as well as other tissues of the human body. Artificial heart valves and working tracheas, as well as muscle, fat, bone, heart, neural and liver cells have all been engineered using amniotic stem cells. Tissues obtained from amniotic cell lines show promise for patients suffering from congenital diseases or malformations of the heart, liver, lungs, kidneys, and cerebral tissue.
Amniotic epithelial cell-derived exosome for treating gestational hypertension disease and application of amniotic epithelial cell-derived exosome
The invention discloses an amniotic epithelial cell-derived exosome for treating gestational hypertension and application thereof, and belongs to the technical field of biological medicines. The exosome (hAECs-exos) is obtained by secreting and extracting human amniotic epithelial cells (hAECs), the particle size distribution of the exosome (hAECs-exos) is 30-150 nm, and the exosome (hAECs-exos) expresses exosome specific markers CD9, CD63 and CD81. The invention also provides a preparation method of the exosome. The preparation method comprises the following steps: isolated culture of hAECs, and ultracentrifugal extraction and identification of the exosome. Animal experiments prove that when the exosome is applied to a gestational hypertension disease model animal in an intravenous injection mode, the blood pressure and urine protein level of the gestational hypertension disease model animal can be remarkably reduced, and the fetal rat dysplasia condition is improved. The invention provides a brand-new and effective biological preparation candidate scheme for the treatment of the gestational hypertension disease.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Use of tacstd2 protein in the preparation of a product for detecting and identifying human amnion epithelial cells
The application discloses application of TACSTD2 protein in preparation of products for detecting and identifying human amniotic epithelial cells, and belongs to the technical field of biological medicines. The application proposes a protein marker for detecting and identifying human amniotic epithelial stem cells, which comprises TACSTD2 protein, or TACSTD2 protein combined with one or more selected from CD29, CD166, CD73, CD90, CD105, CD324, CD326, SSEA4, Nestin and Vimentin. The application further proposes application of a reagent for detecting TACSTD2 protein expression in preparation of products for detecting and identifying human amniotic epithelial cells, which is specifically highly expressed in human amniotic epithelial stem cells and can be used alone or in combination with other cells for detecting and identifying human amniotic epithelial cells.
Owner:SHANGHAI ANKUSHENG MEDICAL BIOTECHNOLOGY CO LTD
Preparation method of human placenta amnion pluripotent stem cells
The invention relates to the technical field of stem cells, in particular to a preparation method of human placenta amnion pluripotent stem cells. The method specifically comprises the following steps: S1, tissue pretreatment and physical pre-layering; s2, carrying out mechanical-enzymatic synergistic dynamic dissociation; s3, gradient purification and washing; s4, performing soft matrix phenotype maintenance culture; according to the method disclosed by the invention, the separation efficiency of amniotic epithelial cells is improved and the enzyme exposure load is reduced through synergistic enzymolysis of Dispase II and Trypsin in combination with weak shearing force generated by the magnetic beads. Meanwhile, SB431542 blocks a signal channel to prevent EMT, a GelMA soft matrix maintains cell phenotypes, and Percoll density gradient centrifugation is matched to improve cell purity.
Owner:ABBVIE (TIANJIN) BIOTECHNOLOGY CO LTD
A radial expansion flexible clamping and stacking device for amnion epithelial stem cell culture dishes
The application discloses a radial expansion type flexible clamping and stacking device for amniotic epithelial stem cell culture dishes, and belongs to the technical field of cell culture engineering. The radial expansion type flexible clamping mechanism can greatly reduce the interference to amniotic epithelial stem cells during clamping of the culture dishes, the design can significantly reduce the displacement amplitude of the culture dishes compared with the large-area adhesion clamping of the traditional clamping mechanism, and effectively prevents uneven distribution of amniotic epithelial cells or falling of the amniotic epithelial cells from the bottom of the culture dishes caused by impact and friction.
Owner:SHANGHAI XUNYUAN BIOTECHNOLOGY CO LTD
Single-cell transcriptome analysis of human amnion
PendingUS20260176686A1HydrolasesMicrobiological testing/measurementSingle cell transcriptomeSignalling molecules
Provided herein include methods, compositions, isolated cells, cell models, and kits suitable for use in profiling various cell types in amnion including amnion epithelial cells, amnion mesenchymal cells, fibroblasts, macrophages, as well as amnion stem cells including amnion epithelial stem cells and amnion mesenchymal stem cells. The present disclosure also discloses novel markers for various cell types in human amnion, including marker genes, transcription factors and signaling molecules associated with various stages of amniotic development. The methods, cell models, and gene signatures disclosed herein can be used for a variety of research, diagnostic, or therapeutic applications.
Owner:CALIFORNIA INST OF TECH
Application of MIF gene silencing in the preparation of drugs for treating premature rupture of membranes (PROM)
PendingCN122075710AThe mechanism of action is clearclearly targetedOrganic active ingredientsAntibody ingredientsGene silencingFoetal membranes
This invention discloses the application of MIF gene silencing in the preparation of drugs for treating premature rupture of membranes (PPROM), belonging to the fields of biomedicine and molecular biology. By collecting fetal membrane tissues from patients with PPROM and normal controls, this invention found that the expression level of MIF protein and the concentration of PGE2 were significantly increased in the PPROM group. Further investigation using siRNA technology to silence the MIF gene in human amniotic epithelial cells revealed that MIF silencing significantly reduced PGE2 levels. This invention is the first to demonstrate that MIF gene silencing can effectively treat PPROM by reducing PGE2 (inhibiting uterine contractions). This invention also provides a pharmaceutical composition containing MIF siRNA. This invention provides a novel molecular target and therapeutic strategy for the treatment of PPROM, with broad clinical application prospects.
Owner:CHONGQING MEDICAL UNIVERSITY
Lentiviral vector-based amniotic cell immortalized line establishment method
The invention relates to the technical field of cytobiology and genes, in particular to an amniotic cell immortalized line establishment method based on a lentiviral vector, which comprises the following steps: acquiring primary cells from amniotic tissues, and removing fibroblast-like cells by a differential adherent culture technology to obtain a high-purity epithelial amniotic cell population. An immortalized gene is introduced into the purified cell by using the constructed lentiviral vector, and a plurality of monoclonal cell strains are established through drug screening and monoclonal separation. By detecting integration sites and expression levels of immortalized genes in all monoclonal strains, candidate cell strains with safe integration sites and stable expression are screened out, and finally the immortalized cell line is determined through passage and functional verification. According to the method, cell source purification and genetic integration evaluation are controlled, an immortalized amniotic epithelial cell line which is consistent in cell phenotype, safe in genetic background and stable in character can be established, and a reliable tool is provided for related research.
Owner:潍坊吉涛医学科技有限公司 +1
Single-cell transcriptome analysis of human amnion
PCT designated stageWO2026136754A1Mammal material medical ingredientsEmbryonic cellsSingle cell transcriptomeSignalling molecules
Provided herein include methods, compositions, isolated cells, cell models, and kits suitable for use in profiling various cell types in amnion including amnion epithelial cells, amnion mesenchymal cells, fibroblasts, macrophages, as well as amnion stem cells including amnion epithelial stem cells and amnion mesenchymal stem cells. The present disclosure also discloses novel markers for various cell types in human amnion, including marker genes, transcription factors and signaling molecules associated with various stages of amniotic development. The methods, cell models, and gene signatures disclosed herein can be used for a variety of research, diagnostic, or therapeutic applications.
Owner:CALIFORNIA INST OF TECH